Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 27, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Arthur He Maintained (BCAB) at Strong Buy with Decreased Target to $7 on, Mar 27th, 2024
Arthur He of HC Wainwright & Co., Maintained "BioAtla, Inc." (BCAB) at Strong Buy with Decreased Target from $10 to $7 on, Mar 27th, 2024.
Arthur has made no other calls on BCAB in the last 4 months.
There is 1 other peer that has a rating on BCAB. Out of the 1 peers that are also analyzing BCAB, 0 agree with Arthur's Rating of Hold.
This is the rating of the analyst that currently disagrees with Arthur
- Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $12 on, Tuesday, December 5th, 2023
